Horizon Discovery Group plc designs, manufactures, and applies gene editing and gene modulation to build cell models that harbour the genetics of human disease in the Americas, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company operates through Products, Services, and Leveraged Research and Development (R&D) segments. It operates a transnational genomics platform, a suite of gene editing tools to alter gene sequence in human or mammalian cell-lines. The company offers various research products, including cell lines that help researchers to understand how complex genetic diseases manifest themselves in patients; research reagents, which enable researchers to silence genes with the use of RNAi and express or overexpress genes through tools, such as cDNA, as well as permanently edit genes with CRISPR reagents; and in vivo research models for specialized R&D applications, and to support preclinical drug development programs. It also provides reference standards that are used as a source of genetically defined, quantitative, sustainable, and independent third-party reference material, as well as for validation and routine performance monitoring of assays; and bio-production cell lines licenses. In addition, the company offers cell and in vivo custom model generation, assay, and genetic and molecular screening services, as well as screening publications. Further, it is involved in the leverages R&D activity. The company serves customers in academic research, drug discovery and manufacturing, and clinical diagnostics markets. It sells its products through direct sales channel and e-commerce platform. The company has a partnership with C4X Discovery Holdings plc to validate novel synthetic oncology targets; and the Rutgers, The State University of New Jersey to develop and commercialize base editing, a gene editing technology. Horizon Discovery Group plc was founded in 2007 and is headquartered in Cambridge, the United Kingdom.
Read More
